Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
The Gilead Asia Pacific Rainbow Grant follows a mission of "Reducing Stigma & Improving Equity" for people living with HIV (PLHIV). The grant supports projects that tackle the multifaceted challenges faced by those living with or at risk of HIV, focusing on three key areas: addressing HIV-related social determinants of health for at-risk populations, integrating mental wellness in HIV care and stigma reduction, and uplifting populations being left behind. The program acknowledges the insidiousness of stigma across various sectors of society—health care, education, workplace, justice systems, families, and communities—and aims to foster a people-centered approach that integrates varied responses to combat stigma and discrimination. Applicants are encouraged to propose projects that align with these focus areas to help improve the equitable quality of life for PLHIV, with a broader goal of ending the HIV epidemic for everyone, everywhere.